Related Experiment Video
Updated: May 10, 2026
Identifying Protein-protein Interaction Sites Using Peptide Arrays
Published on: November 18, 2014
Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic
Taro Noguchi1, Shinya Oishi, Kaori Honda
1Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
Abstract:
MDM2 and MDMX are oncoproteins that negatively regulate the activity and stability of the tumor suppressor protein p53. The inhibitors of protein-protein interactions (PPIs) of MDM2-p53 and MDMX-p53 represent potential anticancer agents. In this study, a novel approach for identifying MDM2-p53 and MDMX-p53 PPI inhibitor candidates by affinity-based screening using a chemical array has been established. A number of compounds from an in-house compound library, which were immobilized onto a chemical array, were screened for interaction with fluorescence-labeled MDM2 and MDMX proteins. The subsequent fluorescent polarization assay identified several compounds that inhibited MDM2-p53 and MDMX-p53 interactions.
Insights
Researchers developed a new method to find potential anticancer drugs by screening chemical arrays for compounds that disrupt MDM2-p53 and MDMX-p53 protein interactions, identifying several promising candidates.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- MDM2 and MDMX are oncoproteins that inhibit the tumor suppressor p53.
- Disrupting MDM2-p53 and MDMX-p53 interactions is a promising anticancer strategy.
- Targeting these protein-protein interactions (PPIs) offers a therapeutic avenue.
Purpose of the Study:
- To establish a novel affinity-based screening approach for identifying inhibitors of MDM2-p53 and MDMX-p53 PPIs.
- To discover novel small molecules that can disrupt these critical oncogenic interactions.
- To validate the identified inhibitors using biophysical assays.
Main Methods:
- Development of a chemical array platform for high-throughput screening.
- Immobilization of an in-house compound library onto the chemical array.
- Screening for interactions with fluorescence-labeled MDM2 and MDMX proteins.
- Utilizing a fluorescence polarization assay to confirm inhibitory activity.
Main Results:
- Successfully established a novel chemical array-based screening method.
- Identified several compounds that interact with and inhibit MDM2-p53 and MDMX-p53 PPIs.
- Demonstrated the utility of the platform for discovering PPI inhibitors.
Conclusions:
- The developed chemical array screening approach is effective for identifying MDM2-p53 and MDMX-p53 PPI inhibitors.
- This method provides a valuable tool for the discovery of novel anticancer agents targeting the p53 pathway.
- The identified compounds warrant further investigation as potential therapeutic candidates.
